These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 16504865

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function.
    Saarilahti K, Kouri M, Collan J, Hämäläinen T, Atula T, Joensuu H, Tenhunen M.
    Radiother Oncol; 2005 Mar; 74(3):251-8. PubMed ID: 15763305
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?
    Jellema AP, Doornaert P, Slotman BJ, Leemans CR, Langendijk JA.
    Radiother Oncol; 2005 Nov; 77(2):164-71. PubMed ID: 16256229
    [Abstract] [Full Text] [Related]

  • 5. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
    Strigari L, Benassi M, Arcangeli G, Bruzzaniti V, Giovinazzo G, Marucci L.
    Int J Radiat Oncol Biol Phys; 2010 May 01; 77(1):269-76. PubMed ID: 20100642
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
    Blanco AI, Chao KS, El Naqa I, Franklin GE, Zakarian K, Vicic M, Deasy JO.
    Int J Radiat Oncol Biol Phys; 2005 Jul 15; 62(4):1055-69. PubMed ID: 15990009
    [Abstract] [Full Text] [Related]

  • 8. Modeling of salivary production recovery after radiotherapy using mixed models: determination of optimal dose constraint for IMRT planning and construction of convenient tools to predict salivary function.
    Ortholan C, Chamorey E, Benezery K, Thariat J, Dassonville O, Poissonnet G, Bozec A, Follana P, Peyrade F, Sudaka A, Gerard JP, Bensadoun RJ.
    Int J Radiat Oncol Biol Phys; 2009 Jan 01; 73(1):178-86. PubMed ID: 18565687
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of irradiated salivary gland function in patients with head and neck tumours treated with radiotherapy.
    Baharudin A, Khairuddin A, Nizam A, Samsuddin AR.
    J Laryngol Otol; 2009 Jan 01; 123(1):108-13. PubMed ID: 18452635
    [Abstract] [Full Text] [Related]

  • 10. Sparing of contralateral major salivary glands has a significant effect on oral health in patients treated with radical radiotherapy of head and neck tumors.
    Beer KT, Zehnder D, Lussi A, Greiner RH.
    Strahlenther Onkol; 2002 Dec 01; 178(12):722-6. PubMed ID: 12491061
    [Abstract] [Full Text] [Related]

  • 11. Salivary gland function and xerostomia in southern Chinese following radiotherapy for nasopharyngeal carcinoma.
    Pow EH, McMillan AS, Leung WK, Wong MC, Kwong DL.
    Clin Oral Investig; 2003 Dec 01; 7(4):230-4. PubMed ID: 12955605
    [Abstract] [Full Text] [Related]

  • 12. Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy.
    Braam PM, Roesink JM, Raaijmakers CP, Busschers WB, Terhaard CH.
    Radiat Oncol; 2007 Jan 05; 2():3. PubMed ID: 17207274
    [Abstract] [Full Text] [Related]

  • 13. A randomized phase III prospective trial of bethanechol to prevent radiotherapy-induced salivary gland damage in patients with head and neck cancer.
    Jham BC, Teixeira IV, Aboud CG, Carvalho AL, Coelho Mde M, Freire AR.
    Oral Oncol; 2007 Feb 05; 43(2):137-42. PubMed ID: 16798061
    [Abstract] [Full Text] [Related]

  • 14. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL, Chao KS, Haughey B.
    Semin Oncol; 2004 Dec 05; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [Abstract] [Full Text] [Related]

  • 15. Intensity-modulated radiation therapy and xerostomia.
    Chambers MS, Weber RS, Garden AS.
    J Calif Dent Assoc; 2006 Sep 05; 34(9):743-8. PubMed ID: 17022299
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function.
    Kwong DL, Pow EH, Sham JS, McMillan AS, Leung LH, Leung WK, Chua DT, Cheng AC, Wu PM, Au GK.
    Cancer; 2004 Oct 01; 101(7):1584-93. PubMed ID: 15378492
    [Abstract] [Full Text] [Related]

  • 18. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome.
    Rhodus NL, Bereuter J.
    J Otolaryngol; 2000 Feb 01; 29(1):28-34. PubMed ID: 10709169
    [Abstract] [Full Text] [Related]

  • 19. The effect of hyperbaric oxygenation on postradiation xerostomia and saliva in patients with head and neck tumours.
    Cankar K, Finderle Z, Jan J.
    Caries Res; 2011 Feb 01; 45(2):136-41. PubMed ID: 21447949
    [Abstract] [Full Text] [Related]

  • 20. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial.
    Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, Leung WK.
    Int J Radiat Oncol Biol Phys; 2006 Nov 15; 66(4):981-91. PubMed ID: 17145528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.